05/12/2026
So what’s going on with the estradiol patch shortage—and why does it keep happening?
The good news: demand for hormone therapy has surged (more women getting care) and the boxed warning was removed in late 2025.
The bad news: there are few manufacturers, plus supply chain constraints—and a system issue that creates bottlenecks. When insurers, pharmacies, and pharmacy benefit managers are connected under the same corporate umbrella, it can restrict which versions can be dispensed and stocked, pushing patients toward higher-cost branded products.
Bottom line: this isn’t just “more people are on HRT.” It’s access, coverage rules, and low-margin generics.
What we’re doing (and what you can ask your clinician about):
• Consider transdermal gels or sprays when patches are unavailable
• Explore alternate patch strengths/dosing strategies when appropriate
• Call around pharmacies to locate stock and confirm NDCs/options
If you’re affected, we can help you pivot safely with a personalized plan.
👉 Book via the link in bio.